NVAX at the crossroad
NVAX had some headwinds news with the small set back on the 2nd stage clinical trial. The 15% drop landed the NVAX at the bottom of the trend line, a confirmed break below low (below 10$ for 2+ trading days) would be a strong sell signal, or a potential rebounded to the up trendline with more support of debunking the allegation.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.